Genelux (NASDAQ:GNLX) CEO Thomas Zindrick Sells 34,463 Shares

Genelux Corporation (NASDAQ:GNLX) CEO Thomas Zindrick sold 34,463 shares of the stock in a transaction dated Monday, August 31st. The stock was sold at an average price of $2.67, for a total value of $92,016.21. Following the sale, the chief executive officer directly owned 1,226,427 shares in the company, valued at $3,274,560.09. This represents a 2.73% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Thomas Zindrick also recently made the following trade(s):

• On Tuesday, August 4th, Thomas Zindrick sold 3,023 shares of Genelux stock. The shares were sold at an average price of $2.95, for a total value of $8,917.85.

Genelux Stock Down 1.9%

Genelux stock traded down $0.05 during midday trading on Wednesday, hitting $2.55. 158,117 shares of the company were exchanged, compared to its average volume of 366,336. Genelux Corporation has a fifty-two week low of $2.29 and a fifty-two week high of $8.53. The business has a fifty day simple moving average of $2.83 and a two-hundred day simple moving average of $2.78.

Genelux (NASDAQ:GNLX) last announced its quarterly earnings results on Thursday, August 13th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.01). As a group, sell-side analysts anticipate that Genelux Corporation will post -0.81 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of GNLX. Citadel Advisors LLC acquired a new stake in Genelux during the second quarter worth $257,000. Strive Financial Group LLC lifted its position in Genelux by 728.7% in the second quarter. Strive Financial Group LLC now owns 41,437 shares of the company’s stock valued at $125,000 after buying an additional 36,437 shares during the last quarter. Bank of America Corp DE purchased a new stake in shares of Genelux in the 2nd quarter valued at approximately $990,000. BlackRock Inc. acquired a new position in shares of Genelux in the 2nd quarter worth approximately $1,323,000. Finally, AMG National Trust Bank purchased a new position in shares of Genelux during the 2nd quarter worth approximately $227,000. Hedge funds and other institutional investors own 37.33% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on GNLX shares. Wall Street Zen raised shares of Genelux from a “strong sell” rating to a “sell” rating in a report on Sunday, August 23rd. Weiss Ratings restated a “sell (e+)” rating on shares of Genelux in a research report on Friday, July 17th. Finally, Benchmark restated a “speculative buy” rating on shares of Genelux in a research report on Tuesday, August 18th. Three research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $18.00.

About Genelux

Genelux Corporation (NASDAQ:GNLX) is a clinical-stage biotechnology company focused on the development of oncolytic virus immunotherapies. Built on a proprietary vaccinia virus platform, the company’s programs are designed to selectively infect and destroy cancer cells while stimulating a systemic immune response. Genelux’s lead candidate, pexastimogene devacirepvec (GL-ONC1), is being evaluated in multiple indications, including peritoneal malignancies and head and neck cancers, where it is administered either intraperitoneally or systemically depending on the trial design.

Genelux’s pipeline leverages its experience with the GL-ONC1 construct to explore combination strategies with chemotherapy and immuno-oncology agents.